GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SSY Group Ltd (HKSE:02005) » Definitions » Net Change in Cash

SSY Group (HKSE:02005) Net Change in Cash : HK$-225 Mil (TTM As of Jun. 2024)


View and export this data going back to 2005. Start your Free Trial

What is SSY Group Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

SSY Group's Net Change in Cash for the six months ended in Jun. 2024 was HK$-51 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-225 Mil.

SSY Group Net Change in Cash Historical Data

The historical data trend for SSY Group's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SSY Group Net Change in Cash Chart

SSY Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 628.48 215.83 5.81 -52.34 -

SSY Group Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 42.32 122.07 -174.41 -50.67 -

SSY Group Net Change in Cash Calculation

SSY Group's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=925.747+-640.194+-304.571+-33.321
=-52

SSY Group's Net Change in Cash for the quarter that ended in Jun. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=322.918+-288.002+-69.013+-16.576
=-51

Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-225 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SSY Group Net Change in Cash Related Terms

Thank you for viewing the detailed overview of SSY Group's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

SSY Group Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SSY Group Ltd (HKSE:02005) » Definitions » Net Change in Cash
Comparable Companies
HKSE:02186 HKSE:00570 HKSE:01558 HKSE:01681 HKSE:03613 HKSE:01349 HKSE:06185 HKSE:02561 HKSE:02877 HKSE:00460 ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ HKSE:03692 NSE:DIVISLAB XTAE:TEVA
Traded in Other Exchanges
N/A
Address
Central Plaza, 18 Harbour Road, Rooms 4902-03, 49th Floor, Wanchai, Hong Kong, HKG
Website
https://www.ssygroup.com.hk
SSY Group Ltd is engaged in the research, development, manufacturing and selling of a wide range of pharmaceutical products, which includes finished medicines of mainly intravenous infusion solution and ampoule injection to hospitals and distributors, bulk pharmaceuticals and medical materials. The company has two reportable segments including intravenous infusion solution and others and medical materials. The company derives a vast majority of its revenue principally from the Intravenous infusion solution and others. Revenue generation is driven mostly by its sales of pharmaceutical products, followed by medical materials.
Executives
Ubs Group Ag 2201 Interest of corporation controlled by you
China Pharmaceutical Company Limited 2101 Beneficial owner
Qu Jiguang 2201 Interest of corporation controlled by you
Si Chuan Ke Lun Yao Ye Gu Fen You Xian Gong Si 2101 Beneficial owner

SSY Group Headlines

No Headlines